Biotech Industry Sees Victory in Appeals Court Ruling on Myriad Patents; Supreme Court Likely to Weigh In

Drug Industry Daily
In a victory for the biotechnology industry, the U.S. Court of Appeals for the Federal Circuit ruled 2–1 to reaffirm its earlier ruling that Myriad Genetics can patent genes related to its breast and ovarian cancer screening system.

To View This Article:


Subscribe To Drug Industry Daily